Narmeen S. Rashid , Avina Rami , Min Lang , Hailey Stoltenberg , Andrew Wolanski , Jolivette Ritzer , Heather Jacene , Praful Ravi
{"title":"Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases","authors":"Narmeen S. Rashid , Avina Rami , Min Lang , Hailey Stoltenberg , Andrew Wolanski , Jolivette Ritzer , Heather Jacene , Praful Ravi","doi":"10.1016/j.clgc.2025.102309","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>While 177Lu-PSMA-617 (LuPSMA) is a proven life-prolonging therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), little is known about its efficacy in patients with central nervous system (CNS) metastasis.</div></span></li><li><span>•</span><span><div>In this case series, some CRPC patients with CNS disease had a partial or mixed intracranial response to LuPSMA, typically combined with brain-directed therapy, but others developed new brain metastasis or experienced neurological decline.</div></span></li><li><span>•</span><span><div>Though LuPSMA appears to have some intracranial activity, a multimodal approach with adjunctive use of local therapy is likely needed for patients with CNS disease.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 2","pages":"Article 102309"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000114","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
While 177Lu-PSMA-617 (LuPSMA) is a proven life-prolonging therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), little is known about its efficacy in patients with central nervous system (CNS) metastasis.
•
In this case series, some CRPC patients with CNS disease had a partial or mixed intracranial response to LuPSMA, typically combined with brain-directed therapy, but others developed new brain metastasis or experienced neurological decline.
•
Though LuPSMA appears to have some intracranial activity, a multimodal approach with adjunctive use of local therapy is likely needed for patients with CNS disease.
期刊介绍:
Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.